Malign ve benign tiroid tümörlerinde PET'de tutulum ile tümör sitopatolojisi, hastalık yaygınlığı ve moleküler belirteçlerin ilişkisi
Özet
In this study; relation of molecular markers such as NIS, Galectin-3, PTEN, Ki-67, p53 with PET positivity and malignity of thyroid lesions were aimed to be explained. Material and Methods: Patients who applied to Ankara University Faculty of MedicineDepartment of Nuclear Medicine for PET imaging was screened for thyroid involvement. Thyroidectomisedpatients that operated after thyoid involvement was seen in PET imaging were included to study. Pathology reports of patients were investigated. Nodule localization in PET report and pathology report were compared. PET positive and negative nodules were determined. 15 patients whose thyroid was involved in PET imaging were included to study. FDG positive 21 nodules were included to study. 13 of them were malign and 8 of them were benign. FDG negative and malign 6 nodules of those patients were also included to study. These nodules were examined for immunohistochemical staining features forGalectin-3, NIS, PTEN, p53 andKi67. RESULTS: In this study 27 nodules of 15 patients were examined for immunohistochemical staining features forGalectin-3, NIS, PTEN, p53 andKi67. They are also evaluated for patients' age, gender and nodule features such as being PET positivite and malign,PET positivite and benign, PET negative and malign. 6 of 8 benign nodules (75%) were not stained with galectin-3. 36,8% of malign nodules were not stained with galectin-3. 12 nodules which were stained with galectin-3 ; stained at least moderately intense or intense.In our study NIS expression was seen more frequently and intense in elderly people.Deficiency of PTEN expression was seen more in malign nodules. PTEN staining was not seen in 42.1% of all malign nodules. Nodules were not stained for p53. Conclusion: As a result, any relation with FDG-PET positivity and Galectin-3, NIS, Ki67, PTEN, p53 expression was not found. New studies are necessary for explaining pathogenesis and role of molecular markers in development of FDG-PET positive thyroid nodules.